MX2016011674A - Combinacion que comprende un inhibidor de btk y un inhibidor de akt. - Google Patents

Combinacion que comprende un inhibidor de btk y un inhibidor de akt.

Info

Publication number
MX2016011674A
MX2016011674A MX2016011674A MX2016011674A MX2016011674A MX 2016011674 A MX2016011674 A MX 2016011674A MX 2016011674 A MX2016011674 A MX 2016011674A MX 2016011674 A MX2016011674 A MX 2016011674A MX 2016011674 A MX2016011674 A MX 2016011674A
Authority
MX
Mexico
Prior art keywords
inhibitor
akt
btk
combination
chloro
Prior art date
Application number
MX2016011674A
Other languages
English (en)
Spanish (es)
Inventor
Kumar Rakesh
A Robell Kimberly
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016011674A publication Critical patent/MX2016011674A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016011674A 2014-03-12 2015-02-24 Combinacion que comprende un inhibidor de btk y un inhibidor de akt. MX2016011674A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461951640P 2014-03-12 2014-03-12
PCT/IB2015/051380 WO2015136398A1 (en) 2014-03-12 2015-02-24 Combination comprising a btk inhibitor and an akt inhibitor

Publications (1)

Publication Number Publication Date
MX2016011674A true MX2016011674A (es) 2017-04-27

Family

ID=52630445

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011674A MX2016011674A (es) 2014-03-12 2015-02-24 Combinacion que comprende un inhibidor de btk y un inhibidor de akt.

Country Status (10)

Country Link
US (2) US20170020878A1 (cg-RX-API-DMAC7.html)
EP (1) EP3116546A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017507963A (cg-RX-API-DMAC7.html)
KR (1) KR20160127754A (cg-RX-API-DMAC7.html)
CN (1) CN106456642A (cg-RX-API-DMAC7.html)
AU (1) AU2015228475B9 (cg-RX-API-DMAC7.html)
CA (1) CA2942204A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016011674A (cg-RX-API-DMAC7.html)
RU (1) RU2016139697A (cg-RX-API-DMAC7.html)
WO (1) WO2015136398A1 (cg-RX-API-DMAC7.html)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
NZ594064A (en) * 2009-01-30 2012-08-31 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US8940725B2 (en) 2010-05-31 2015-01-27 Ono Pharmaceutical Co., Ltd. Purinone derivative
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
ES2590491T3 (es) 2011-05-17 2016-11-22 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
WO2013010869A1 (en) 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ, インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
CA2852964A1 (en) 2011-11-03 2013-05-10 F. Hoffmann-La Roche Ag Bicyclic piperazine compounds
BR112014012727B1 (pt) 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
WO2013161848A1 (ja) 2012-04-27 2013-10-31 カルナバイオサイエンス株式会社 新規1,2,4-トリアジン誘導体
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
CN104487441B (zh) 2012-06-18 2018-06-01 普林斯匹亚生物制药公司 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶

Also Published As

Publication number Publication date
US20170020878A1 (en) 2017-01-26
CN106456642A (zh) 2017-02-22
KR20160127754A (ko) 2016-11-04
WO2015136398A1 (en) 2015-09-17
JP2017507963A (ja) 2017-03-23
AU2015228475B2 (en) 2017-08-17
AU2015228475A1 (en) 2016-09-01
US20190151319A1 (en) 2019-05-23
RU2016139697A (ru) 2018-04-12
RU2016139697A3 (cg-RX-API-DMAC7.html) 2018-10-19
AU2015228475B9 (en) 2017-09-21
CA2942204A1 (en) 2015-09-17
EP3116546A1 (en) 2017-01-18

Similar Documents

Publication Publication Date Title
ZA202401324B (en) Tyrosine kinase inhibitors
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
HK1211942A1 (en) Pyrazolopyrimidine compounds as kinase inhibitors
PH12017500583B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EP4681737A3 (en) Salts and solid form of a btk inhibitor
CA2983481A1 (en) Janus kinase inhibitor
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
NZ779654A (en) Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
HK1247850A1 (zh) Pd-1 拮抗剂与egfr 抑制剂的组合
MX2017012411A (es) Co-cristales de un inhibidor de tirosina cinasa de bruton.
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
MY190835A (en) Bicyclic heterrocyclic derivatives as bromodomain inhibitors
WO2016133903A3 (en) Combination therapy for cancer treatment
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
HK1252425A1 (zh) 用於治疗脱髓鞘疾病的三唑类药物
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
MX376029B (es) Compuestos de isoindol.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MX2018004879A (es) Nuevos derivados de piridona y su uso como inhibidores de quinasas.
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2